Brigitte Kolb

6.6k total citations
25 papers, 728 citations indexed

About

Brigitte Kolb is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Brigitte Kolb has authored 25 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 11 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Brigitte Kolb's work include Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (6 papers). Brigitte Kolb is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (7 papers) and Protein Degradation and Inhibitors (6 papers). Brigitte Kolb collaborates with scholars based in France, United States and Switzerland. Brigitte Kolb's co-authors include Philippe Moreau, Xavier Leleu, Michel Attal, Thierry Façon, Denis Caillot, Murielle Roussel, Cyrille Hulin, Lotfi Benboubker, Hervé Avet‐Loiseau and Stéphane Minvielle and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cellular Immunology.

In The Last Decade

Brigitte Kolb

25 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brigitte Kolb France	9	426	373	243	238	214	25	728
David H. Vesole United States	9	164 0.4×	178 0.5×	196 0.8×	195 0.8×	50 0.2×	30	444
Roberto Guariglia Italy	11	298 0.7×	136 0.4×	98 0.4×	147 0.6×	36 0.2×	39	460
Atsushi Shinagawa Japan	13	208 0.5×	142 0.4×	134 0.6×	144 0.6×	35 0.2×	39	446
Fontanet Bijou France	11	131 0.3×	117 0.3×	234 1.0×	233 1.0×	45 0.2×	46	467
Annette Hänel Germany	8	134 0.3×	91 0.2×	462 1.9×	307 1.3×	109 0.5×	13	639
Vassiliki Grigoraki Greece	8	458 1.1×	309 0.8×	198 0.8×	279 1.2×	20 0.1×	9	656
Sotirios Sachanas Greece	12	109 0.3×	111 0.3×	209 0.9×	146 0.6×	46 0.2×	34	384
Tariq Muzzafar United States	14	149 0.3×	95 0.3×	220 0.9×	152 0.6×	48 0.2×	34	507
Giulia Cervetti Italy	14	131 0.3×	63 0.2×	341 1.4×	252 1.1×	103 0.5×	37	615
Cindy Varga United States	17	371 0.9×	519 1.4×	48 0.2×	266 1.1×	26 0.1×	60	746

Countries citing papers authored by Brigitte Kolb

Since Specialization

Citations

This map shows the geographic impact of Brigitte Kolb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Kolb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Kolb more than expected).

Fields of papers citing papers by Brigitte Kolb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Kolb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Kolb. The network helps show where Brigitte Kolb may publish in the future.

Co-authorship network of co-authors of Brigitte Kolb

This figure shows the co-authorship network connecting the top 25 collaborators of Brigitte Kolb. A scholar is included among the top collaborators of Brigitte Kolb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brigitte Kolb. Brigitte Kolb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Merz, Maximilian, Isabelle Vande Broek, Brigitte Kolb, et al.. (2019). Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey. Blood. 134(Supplement_1). 3115–3115. 5 indexed citations

Hulin, Cyrille, Philippe Moreau, Michel Attal, et al.. (2019). Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.. Journal of Clinical Oncology. 37(15_suppl). 8042–8042. 3 indexed citations

Hulin, Cyrille, Philippe Moreau, Michel Attal, et al.. (2019). PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY. HemaSphere. 3(S1). 252–252. 4 indexed citations

Leleu, Xavier, Guillemette Fouquet, Lionel Karlin, et al.. (2017). Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03.. Journal of Clinical Oncology. 35(15_suppl). 8004–8004. 1 indexed citations

Bridoux, Frank, Brigitte Pegourié, Karine Augeul-Meunier, et al.. (2016). Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)). Blood. 128(22). 978–978. 8 indexed citations

Wynckel, Alain, et al.. (2013). Étude comparative du dosage des chaînes légères libres d’immunoglobulines par technique Freelite™ (The Binding Site) et N Latex FLC (Siemens). Annales de biologie clinique. 71(1). 13–19. 10 indexed citations

Wynckel, Alain, et al.. (2013). Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods. Annales de biologie clinique. 71(1). 13–19. 9 indexed citations

Moreau, Philippe, Brigitte Kolb, Cyrille Hulin, et al.. (2013). Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES. Blood. 122(21). 1933–1933. 5 indexed citations

Kolb, Brigitte, Cyrille Hulin, Denis Caillot, et al.. (2012). Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.. Journal of Clinical Oncology. 30(15_suppl). 8009–8009. 14 indexed citations

10.

Rodon, Philippe, Cyrille Hulin, Brigitte Pegourié, et al.. (2012). Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial. Blood. 120(21). 4044–4044. 5 indexed citations

11.

Brion, A., Beatrice Mahé, Brigitte Kolb, et al.. (2011). Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplantation. 47(4). 542–548. 19 indexed citations

12.

Desport, Éstelle, Claire Aguilar, David Lavergne, et al.. (2011). Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex. Amyloid. 18(sup1). 145–147. 3 indexed citations

13.

Avet‐Loiseau, Hervé, Xavier Leleu, Murielle Roussel, et al.. (2010). Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p). Journal of Clinical Oncology. 28(30). 4630–4634. 298 indexed citations

14.

Jaccard, Arnaud, Véronique Leblond, Bruno Royer, et al.. (2010). Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial. Blood. 116(21). 1344–1344. 5 indexed citations

15.

Chaoui, Driss, Xavier Leleu, Murielle Roussel, et al.. (2009). Has the Prognostic of Primary Plasma Cell Leukemia Improved with New drugs?. Blood. 114(22). 3869–3869. 3 indexed citations

16.

Lebon, Delphine, Bérengère Gruson, Réda Garidi, et al.. (2009). Bortezomib, Doxorubicin and Dexamethasone (PAD) Prior to High-Dose Melphalan / Autologous Stem Cell Transplantation for Newly Diagnosed Plasma Cell Dycrasias.. Blood. 114(22). 4960–4960. 2 indexed citations

17.

Soussain, Carole, Khê Hoang‐Xuan, Luc Taillandier, et al.. (2008). Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal of Clinical Oncology. 26(15). 2512–2518. 214 indexed citations

18.

Soussain, Carole, Khê Hoang‐Xuan, Luc Taillandier, et al.. (2006). Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.. Blood. 108(11). 402–402. 6 indexed citations

19.

Kolb, Brigitte, Richard E. Buller, Joseph P. Connor, Philip J. DiSaia, & M L Berman. (1992). Effects of early postoperative chemotherapy on wound healing.. PubMed. 79(6). 988–92. 34 indexed citations

20.

Lohmann‐Matthes, Marie‐Luise, Brigitte Kolb, & H.G. Meerpohl. (1978). Susceptibility of malignant and normal target cells to the cytotoxic action of bone-marrow macrophages activated in vitro with the macrophage cytotoxicity factor (MCF). Cellular Immunology. 41(2). 231–239. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact